Oklahoma Right to Try Act expands access to experimental drugs, devices for ...

Daily Journal - 10 hours ago
Harada was accepted into a...

Should CT give terminally ill patients the 'right to try' unapproved treatments?

The CT Mirror - 6 days ago
Then, last March, she was...

Right to Try law would help terminal patients

Jackson Clarion Ledger - 1 week ago
The ALS Association of Louisiana...

Reflecting on 35 years of innovation in JEMS

JEMS.com - 4 days ago
Our visionary, specially focused...

Advocating for those who need us

McKnight's Long Term Care News - 4 days ago
Providing the best care for our...

Medical Homes: Cost Effects of Utilization by Chronically Ill Patients

AJMC.com Managed Markets Network - 5 days ago
This methodology encourages...

Datensicherungsanbieter Storix® kündigt Support für SUSE Linux Enterprise 12 an

SYS-CON Media (press release) - 3 days ago
SUSE Linux Enterprise Server 12...

Highland Oaks Middle wins Miami-Dade County track title

MiamiHerald.com - 7 days ago
The Wheels & Waves event...

Is police use of naloxone really saving lives?

EMS1.com - 2 weeks ago
In 2013, at least five states or...


Music Indistry News Network - 5 days ago
Opening Ceremonies are sponsored...

News via Google. See more news matching 'als expanded access'


Expanded Access

Bringing Research and Patients Together

Our Expanded Access platform is meant to do two things:

  1. Empower patients with access to new treatments that are in clinical research.
  2. Empower further research with clinical data from those patients.

For someone with a quick-killer disease, participating in clinical research may be the only way to access a new medicine that might help him live longer.  He may be willing to accept some uncertainty, considering the alternative.  So for patients, there’s a lot of overlap between treatment exploration and research.

But what about patients who cannot get into clinical trials?  Can they still take part in research and explore investigational treatment?

Yes, they can, but only through what are called Expanded Access programs (EAPs).  These are meant to include a much broader group of patients than traditional clinical trials, sometimes exclusively those patients who don’t meet clinical trial enrollment criteria or who otherwise cannot get into trials.

ALS-ETF is bringing a new kind of Expanded Access to the ALS community, to make a groundbreaking impact in the treatment landscape for patients as well as the research that’s powered by patient data.

Learn more about Expanded Access programs here.

Learn more about our research goals here.